Sabra Health Care REIT, Inc. (SBRA)
NASDAQ: SBRA · Real-Time Price · USD
20.51
+0.23 (1.11%)
At close: Apr 28, 2026, 4:00 PM EDT
20.51
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:15 PM EDT
Sabra Health Care REIT Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Sabra Health Care REIT stock have an average target of 22, with a low estimate of 21 and a high estimate of 24. The average target predicts an increase of 7.26% from the current stock price of 20.51.
Analyst Consensus: Buy
* Price targets were last updated on Mar 26, 2026.
Analyst Ratings
The average analyst rating for Sabra Health Care REIT stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 6 | 6 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $21 → $22 | Buy | Maintains | $21 → $22 | +7.26% | Mar 26, 2026 |
| Truist Securities | Truist Securities | Hold Maintains $21 → $22 | Hold | Maintains | $21 → $22 | +7.26% | Mar 13, 2026 |
| Scotiabank | Scotiabank | Hold Maintains $20 → $21 | Hold | Maintains | $20 → $21 | +2.39% | Mar 2, 2026 |
| UBS | UBS | Hold Maintains $20 → $21 | Hold | Maintains | $20 → $21 | +2.39% | Feb 19, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $21 → $24 | Strong Buy | Maintains | $21 → $24 | +17.02% | Feb 18, 2026 |
Financial Forecast
Revenue This Year
833.97M
from 775.76M
Increased by 7.50%
Revenue Next Year
909.64M
from 833.97M
Increased by 9.07%
EPS This Year
0.74
from 0.64
Increased by 15.21%
EPS Next Year
0.79
from 0.74
Increased by 6.80%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 960.4M | 1.1B | ||||
| Avg | 834.0M | 909.6M | ||||
| Low | 721.7M | 770.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | 23.8% | 28.4% | ||||
| Avg | 7.5% | 9.1% | ||||
| Low | -7.0% | -7.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.88 | 0.86 | |
| Avg | 0.74 | 0.79 | |
| Low | 0.65 | 0.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.8% | 16.8% | |
| Avg | 15.2% | 6.8% | |
| Low | 1.1% | -0.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.